Recommendations for evaluation and management of bone disease in HIV

Clinical Infectious Diseases

Volumn 60, Issue 8, 2015, Pages 1242-1251

  Brown, Todd T ^a   Hoy, Jennifer ^b   Borderi, Marco ^c   Guaraldi, Giovanni ^d   Renjifo, Boris ^e   Vescini, Fabio ^f   Yin, Michael T ^g   Powderly, William G ^h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e ABBVIE INC   (United States)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g Department of Medicine   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone disease; fragility fracture; human immunodeficiency virus; osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; CORTICOSTEROID; DENOSUMAB; ERGOCALCIFEROL; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT;

ARTICLE; BONE DENSITY; BONE DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE MODIFICATION; MEDICAL SPECIALIST; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PATIENT MONITORING; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SECONDARY OSTEOPOROSIS; SPINE FRACTURE; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; ADULT; AGED; COMPLICATION; DECISION SUPPORT SYSTEM; FEMALE; FRACTURES, BONE; HIV INFECTIONS; MALE; MIDDLE AGED; PHOTON ABSORPTIOMETRY; VERY ELDERLY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; DECISION SUPPORT TECHNIQUES; FEMALE; FRACTURES, BONE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 84926633782     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ010     Document Type: Article

References (57)

1. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-46.
2. European AIDS Clinical Society. European AIDS Clinical Society (EACS) guidelines, version 7, 2013. Available at: http://www. eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Accessed 21 July 2014.
3. Asboe D, Aitken C, Boffito M, et al. British HIVAssociation guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012; 13:1-44.
4. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2014. Available at: http://nof.org/files/nof/public/content/ file/2610/upload/895.pdf. Accessed 21 July 2014.
5. National Osteoporosis Guideline Group. Osteoporosis: clinical guideline for prevention and treatment. 2013. Available at: www.shef.ac.uk/ NOGG/. Accessed 21 July 2014.
6. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAXand its applications to clinical practice. Bone 2009; 44: 734-43.
7. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX® with and without bone mineral density. Calcif Tissue Int 2012; 90: 1-13.
8. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Available at: http://www. who.int/chp/topics/Osteoporosis.pdf. Accessed 21 July 2014.
9. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11:75-91.
10. Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366: 225-33.
11. Negredo E, Bonjoch A, Gomez-Mateu M, et al. Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan. PLoS One 2012; 7:e46031.
12. International Society for Clinical Densitometry. 2007 official positions and pediatric official positions of the International Society for Clinical Densitometry, 2007. Available at: http://www.iscd.org/officialpositions/ official-positions/. Accessed 21 July 2014.
13. Walker Harris V, Althoff K, Reynolds S, et al. Incident bone fracture in men with, or at risk for, HIV-infection in the Multicenter AIDS Cohort Study (MACS), 1996-2011. Abstract MOPE086. In: Program and abstracts of the XIX International AIDS Conference, Washington, DC. J Int AIDS Soc 2012; 15(suppl 32).
14. Young B, Dao CN, Buchacz K, Baker R, Brooks JT; HIV Outpatient Study (HOPS) Investigators. HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-8.
15. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012; 205:S391-8.
16. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008; 45:221-58.
17. McCloskey EV, Vasikaran S, Cooper C. FRAX® position development conference members. Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011; 14:220-2.
18. Li V, Soresi M, Giannitrapani L, et al. Dairy calcium intake and lifestyle risk factors for bone loss in HIV-infected and uninfected Mediterranean subjects. BMC Infect Dis 2012; 12:192.
19. Leite LH, Sampaio AB. Dietary calcium, dairy food intake and metabolic abnormalities in HIV-infected individuals. J Hum Nutr Diet 2010; 23:535-43.
20. Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005; 6:145-50.
21. Viard JP, Souberbielle JC, Kirk O, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25:1305-15.
22. Allavena C, Delpierre C, Cuzin L, et al. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother 2012; 67:2222-30.
23. Vescini F, Cozzi-Lepri A, Borderi M, et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr 2011; 58:163-72.
24. Gangcuangco LM, Chow DC, Liang CY, et al. Predictors of 25-hydroxyvitamin D levels in HIV-infected patients in Hawai'i. Hawaii J Med Public Health 2013; 72:197-201.
25. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-8.
26. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
27. Fux CA, Baumann S, Furrer H, Mueller NJ. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?. AIDS 2011; 25:876-8.
28. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81.
29. Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. Arch Biochem Biophys 2010; 503:66-77.
30. Bruyere O, Reginster JY. Vitamin D status and response to antiosteoporotic therapy. Womens Health (Lond Engl) 2008; 4:445-7.
31. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20:239-44.
32. Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 2009; 85:398-404.
33. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001; 15:975-82.
34. Aberg JA, Kaplan JE, Libman H, et al. HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651-81.
35. Law MR, Cheng R, Hackshaw AK, Allaway S, Hale AK. Cigarette smoking, sex hormones and bone density in women. Eur J Epidemiol 1997; 13:553-8.
36. Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983; 117:651-8.
37. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473-82.
38. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-Associated osteopenia/osteoporosis. HIV Clin Trials 2004; 5:269-77.
39. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38:426-31.
40. Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-Treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92:1283-8.
41. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS 2009; 23:1297-310.
42. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-Associated osteopenia and osteoporosis. AIDS 2009; 23:51-7.
43. Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab 2012; 97:1922-8.
44. Rozenberg S, Lanoy E, Bentata M, et al. Effect of alendronate on HIV-Associated osteoporosis: a randomized, double-blind, placebocontrolled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses 2012; 28:972-9.
45. Siminoski K, Jiang G, Adachi JD, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int 2005; 16:403-10.
46. Leib ES, Lewiecki EM, Binkley N, Hamdy RC, International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7:1-6.
47. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15:792-8.
48. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-Treated women: the fracture intervention trial. J Bone Miner Res 2004; 19:1250-8.
49. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18:1051-6.
50. Roux C, Garnero P, Thomas T, et al. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 2005; 72:26-31.
51. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
52. Chesnut CH. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Drugs 2006; 66:1351-9.
53. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077-82.
54. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-52.
55. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003-8.
56. Clay PG, Voss LE, Williams C, Daume EC. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacotherapy 2008; 42:670-9.
57. Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-Tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl) 2011; 3:53-9.